Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26.50 on Endo Health Solutions on Lower Guidance

Share:
Related ENDP
Endo International Notifies Vivus It Will End Its Commercial Supply And License Agreements Related To Avanafil
Watch Out Below, Endo International Investors, Management Is Doubling Down On Weak Assets

Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions (NASDAQ: ENDP) but reduced its price target from $40 to $38.

Stifel Nicolaus commented, "As hoped for, Endo finally put forth what we consider realistic guidance following several over-promises in 2012 that culminated in December's guidance pull and a CEO change by May 2013. … Though guidance is lower than our already modest expectations, we favor this conservative outlook on the year, and look for potential strategic shift with the upcoming CEO change. We are reducing our estimates (2013 $4.50, 2014 trough $4.00) and lowering our target price from $40 to $38 to reflect new guidance."

Endo Health Solutions closed at $26.25 on Thursday.

Latest Ratings for ENDP

DateFirmActionFromTo
Jan 2016BarclaysInitiates Coverage onEqual-weight
Nov 2015Mizuho SecuritiesDowngradesBuyNeutral
Nov 2015Standpoint ResearchUpgradesHoldBuy

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ENDP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters